Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | CA1 | P00915 | 1/20 | 0.49 |
| ▸ | CA2 | P00918 | 1/20 | 0.49 |
| ▸ | CA6 | P23280 | 1/20 | 0.49 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.49 |
| ▸ | CA7 | P43166 | 1/20 | 0.49 |
| ▸ | CA9 | Q16790 | 1/20 | 0.49 |
| ▸ | TP53 | P04637 | 6/20 | 0.45 |
| ▸ | P2RX7 | Q99572 | 3/20 | 0.44 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.41 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.41 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.41 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8358603 | 0.86 | TP53 (0.53) | POLBCA1CA2CA6OPRK1 | |
| SCHEMBL3695224 | 0.82 | CA1 (0.52) | POLBCA1CA2CA6OPRK1 | |
| SCHEMBL8358594 | 0.77 | CA1 (0.61) | POLBCA1CA2CA6OPRK1 | |
| SCHEMBL17195404 | 0.77 | ALDH1A1 (0.40) | POLBTP53P2RX7 | |
| SCHEMBL8358591 | 0.77 | PIK3C3 (0.36) | POLBTP53P2RX7KCNH2 | |
| SCHEMBL14138987 | 0.77 | TP53 (0.46) | POLBCA1CA2CA6OPRK1 | |
| SCHEMBL15683644 | 0.76 | CA1 (0.59) | POLBCA1CA2CA6OPRK1 | |
| SCHEMBL10053487 | 0.75 | POLB (0.62) | POLBCA1CA2CA6OPRK1 | |
| SCHEMBL12445151 | 0.74 | CA1 (0.47) | POLBCA1CA2CA6OPRK1 | |
| SCHEMBL13492110 | 0.74 | CA1 (0.47) | POLBCA1CA2CA6OPRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023109883-A1 | AROMATIC HETEROCYCLE-SUBSTITUTED COMPOUNDS, AND PREPARATION METHOD THEREFOR AND USE THEREOF | 上海翊石医药科技有限公司 | 2023-06-22 | — | — | WO | disclosed |
| US-20170050964-A1 | LACTAM-CONTAINING COMPOUNDS AND DERIVATIVES THEREOF AS FACTOR XA INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2017-02-23 | — | — | US | disclosed |
| US-20150210691-A1 | LACTAM-CONTAINING COMPOUNDS AND DERIVATIVES THEREOF AS FACTOR XA INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2015-07-30 | — | — | US | disclosed |
| US-20140113892-A1 | LACTAM-CONTAINING COMPOUNDS AND DERIVATIVES THEREOF AS FACTOR XA INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-04-24 | — | — | US | disclosed |
| US-8470854-B2 | Lactam-containing compounds and derivatives thereof as factor XA inhibitors | BRISTOL-MEYERS SQUIBB COMPANY (US) | 2013-06-25 | — | — | US | disclosed |
| US-20120201816-A1 | LACTAM-CONTAINING COMPOUNDS AND DERIVATIVES THEREOF AS FACTOR XA INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-08-09 | — | — | US | disclosed |
| US-8188120-B2 | Lactam-containing compounds and derivatives thereof as factor Xa inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-05-29 | — | — | US | disclosed |
| US-20110212930-A1 | LACTAM-CONTAINING COMPOUNDS AND DERIVATIVES THEREOF AS FACTOR XA INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-09-01 | — | — | US | disclosed |
| US-7960411-B2 | Lactam-containing compounds and derivatives thereof as factor Xa inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-06-14 | — | — | US | disclosed |
| US-7960411-B2 | Lactam-containing compounds and derivatives thereof as factor Xa inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-06-14 | — | — | US | disclosed |
| US-7338963-B2 | Lactam-containing compounds and derivatives thereof as factor Xa inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-03-04 | — | — | US | disclosed |
| US-7338963-B2 | Lactam-containing compounds and derivatives thereof as factor Xa inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-03-04 | — | — | US | disclosed |
| US-20070135426-A1 | LACTAM-CONTAINING COMPOUNDS AND DERIVATIVES THEREOF AS FACTOR XA INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2007-06-14 | — | — | US | disclosed |
| US-20070135426-A1 | LACTAM-CONTAINING COMPOUNDS AND DERIVATIVES THEREOF AS FACTOR XA INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2007-06-14 | — | — | US | disclosed |
| US-20070135428-A1 | LACTAM CONTAINING CYCLIC DIAMINES AND DERIVATIVES AS FACTOR XA INHIBITORS | QIAO JENNIFER X | 2007-06-14 | — | — | US | disclosed |
| US-20070135428-A1 | LACTAM CONTAINING CYCLIC DIAMINES AND DERIVATIVES AS FACTOR XA INHIBITORS | QIAO JENNIFER X | 2007-06-14 | — | — | US | disclosed |
| US-7205318-B2 | Lactam-containing cyclic diamines and derivatives as a factor Xa inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-04-17 | — | — | US | disclosed |
| US-7205318-B2 | Lactam-containing cyclic diamines and derivatives as a factor Xa inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-04-17 | — | — | US | disclosed |
| WO-2004082687-A1 | LACTAM-CONTAINING CYCLIC DIAMINES AND DERIVATIVES AS FACTOR XA INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2004-09-30 | — | — | WO | disclosed |
| WO-2003026652-A1 | LACTAM-CONTAINING COMPOUNDS AND DERIVATIVES THEREOF AS FACTOR XA INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2003-04-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120201816-A1 | LACTAM-CONTAINING COMPOUNDS AND DERIVATIVES THEREOF AS FACTOR XA INHIBITORS | F12, F2, CPB1 | POLB 2765/4885CA1 414/4885CA2 1646/4885 |
| US-20150210691-A1 | LACTAM-CONTAINING COMPOUNDS AND DERIVATIVES THEREOF AS FACTOR XA INHIBITORS | F12, F2, CPB1 | POLB 2831/4885CA1 374/4885CA2 1492/4885 |
| US-20070135428-A1 | LACTAM CONTAINING CYCLIC DIAMINES AND DERIVATIVES AS FACTOR XA INHIBITORS | F12, F2, PEPD | POLB 2080/4885CA1 232/4885CA2 1540/4885 |
| US-20170050964-A1 | LACTAM-CONTAINING COMPOUNDS AND DERIVATIVES THEREOF AS FACTOR XA INHIBITORS | F12, F2, CPB1 | POLB 2765/4885CA1 414/4885CA2 1646/4885 |
| US-20110212930-A1 | LACTAM-CONTAINING COMPOUNDS AND DERIVATIVES THEREOF AS FACTOR XA INHIBITORS | F12, F2, CPB1 | POLB 2765/4885CA1 414/4885CA2 1646/4885 |
| US-20140113892-A1 | LACTAM-CONTAINING COMPOUNDS AND DERIVATIVES THEREOF AS FACTOR XA INHIBITORS | F12, F2, CPB1 | POLB 2831/4885CA1 374/4885CA2 1492/4885 |
| US-20070135426-A1 | LACTAM-CONTAINING COMPOUNDS AND DERIVATIVES THEREOF AS FACTOR XA INHIBITORS | F12, F2, CPB1 | POLB 2831/4885CA1 374/4885CA2 1492/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.